The Liver Cancer Special Interest Group (LC-SIG) is a community of investigators focused on the prevention, diagnosis, and treatment of hepatobiliary malignancies. The LC-SIG sponsors programs at the AASLD annual meeting regarding emerging topics in Liver Cancer. These symposia are dynamic, interactive and informative.
The Liver Transplantation SIG provides a forum within AASLD for the exploration of topics of common interest to hepatologists, surgeons and other health care professionals with a primary interest in liver transplantation and hepatobiliary surgery. The steering committee is interdisciplinary, mirroring patterns of care for patients with these conditions.
The goal of the Pediatric Special Interest Group is to promote liver-related issues that affect infants, children and adolescents. The Pediatric SIG supports AASLD missions through committee memberships, educational programming and networking with related academic societies.
Benjamin Philosophe, Russell Noel Wesson – 20 May 2022
Lukas Hartl, Katharina Haslinger, Martin Angerer, Georg Semmler, Mathias Schneeweiss‐Gleixner, Mathias Jachs, Benedikt Simbrunner, David Josef Maria Bauer, Ernst Eigenbauer, Robert Strassl, Monika Breuer, Oliver Kimberger, Daniel Laxar, Katharina Lampichler, Emina Halilbasic, Albert Friedrich Stättermayer, Ahmed Ba‐Ssalamah, Mattias Mandorfer, Bernhard Scheiner, Thomas Reiberger, Michael Trauner – 20 May 2022
Alexandra C. Bolognese, David P. Foley, Carrie J. Sparks, Adam K. Schneider, Anthony M. D'Alessandro, Nikole A. Neidlinger – 20 May 2022 – We perform routine preprocurement image‐guided percutaneous liver biopsies on potential donation after circulatory death (DCD) liver donors. The purpose of this study was to examine the impact of preprocurement liver biopsy on the use of livers from DCD donors.
Einar S. Björnsson, Inmaculada Medina‐Caliz, Raul J. Andrade, M. Isabel Lucena – 20 May 2022 – Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune‐like hepatitis (DI‐AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to define and review the published evidence of suspected DI‐AILH.
Ling Li, Yicheng Zhang, Yang Zhou, Haijie Hu, Yizong Hu, Christos Georgiades, Hai‐Quan Mao, Florin M. Selaru – 20 May 2022
Nidhi Jalan‐Sakrikar, Teresa Brevini, Robert C. Huebert, Fotios Sampaziotis – 20 May 2022 – The burden of liver diseases is increasing worldwide, with liver transplantation remaining the only treatment option for end‐stage liver disease. Regenerative medicine holds great potential as a therapeutic alternative, aiming to repair or replace damaged liver tissue with healthy functional cells. The properties of the cells used are critical for the efficacy of this approach.